Not only has Su Metcalfe’s treatment succeeded in early trials, it involves zero drugs and no side effects—and it could begin human trials as soon as 2020.
Category: biotech/medical – Page 2041
Oklahoma Attorney General Mike Hunter had claimed that J&J and its pharmaceutical subsidiary Janssen aggressively marketed to doctors and downplayed the risks of opioids as early as the 1990s. The state said J&J’s sales practices created an oversupply of the addictive painkillers and “a public nuisance” that upended lives and would cost the state $12.7 billion to $17.5 billion. The state was seeking more than $17 billion from the company.
J&J, which marketed the opioid painkillers Duragesic and Nucynta, has denied any wrongdoing. Lawyers for the company disputed the legal basis Oklahoma used to sue J&J, relying on a “public nuisance” claim. They said the state has previously limited the act to disputes involving property or public spaces.
Investors were expecting J&J to be fined between $500 million and $5 billion, according to Evercore ISI analyst Elizabeth Anderson.
In one of the largest studies of its kind, researchers at Orlando Health are making new progress in finding ways to detect a traumatic yet sinister brain injury—and getting closer to preventing further damage.
Subconcussive injuries often show no symptoms or immediate effects, but can cause wear and tear on the brain over time with repeated injuries. The latest study, published in the journal BMJ Paediatrics Open, includes more than 700 emergency room patients—children and adults. The study gets us closer to developing a standard blood test to spot these injuries as early as possible.
“A unique feature of this study is that it includes patients who hit their heads but have no symptoms,” said Linda Papa, MD, lead author of the study and emergency medicine doctor at Orlando Health. “This group is rarely—if ever—included in biomarker studies.”
Mammals evolved in the face of fluctuating food availability. How the immune system adapts to…
ATLANTA—Targeting specific areas of the measles virus polymerase, a protein complex that copies the viral genome, can effectively fight the measles virus and be used as an approach to developing new antiviral drugs to treat the serious infectious disease, according to a study by the Institute for Biomedical Sciences at Georgia State University published in PLoS Pathogens.
Measles is a highly contagious virus that can lead to serious health complications and death. It begins with a fever, cough, runny nose and red eyes followed by a rash of tiny, red spots that starts at the head and spreads to the rest of the body. Although declared eliminated in the United States in 2000, the Centers for Disease Control and Prevention says the U.S. is experiencing the greatest number of measles cases reported since the early 1990s.
While an effective vaccine exists, there has been a steady decline in the number of people being vaccinated against the measles virus. Most new cases were among unvaccinated individuals, making the development of an effective treatment strategy complementing vaccination a public health priority. There are no antivirals licensed to treat measles. The new study identified a novel protein interface in the polymerase complex that is pivotal for the regulation of polymerase activity, providing a new objective for target-based antiviral drug discovery.
Scientists have identified a class of drugs that may have potential to treat a rare and deadly form of brain cancer that affects young children.
The research team, led by Ranjit Bindra, MD, PhD, and colleagues at the Yale Cancer Center, also included co-senior authors Charles Brenner, PhD, professor and DEO of biochemistry at the University of Iowa Carver College of Medicine, and Michael E. Berens, PhD, from the Translational Genomics Research Institute in Phoenix.
The findings, published Aug. 22 in Nature Communications, focus on Diffuse Intrinsic Pontine Glioma (DIPG), a rare, incurable cancer that affects the brainstem in children under age 10. Previous work had identified mutations in a gene called PPM1D as a cause of this cancer.
You are what you eat—right down to the microbiome living in your gut. Diet can affect which microbes are in the intestinal tract, and research has shown that harmful gut microbiome changes can lead to illnesses such as heart disease, obesity and cancer. Today, scientists will report the development of molecules that can change, or remodel, unhealthful gut microbiomes in mice into more healthful ones. The research could also someday be applied to other conditions related to diet.
The researchers will present their results at the American Chemical Society (ACS) Fall 2019 National Meeting & Exposition.
“The gut microbiome contains hundreds of different species of bacteria and is where the largest concentration of bacteria living in us resides,” says M. Reza Ghadiri, Ph.D., leader of the study. “If we all ate a healthy diet, exercised and didn’t age, we wouldn’t have problems with our gut microbiome and many diseases. But, that’s not how all people live. Current methods aimed at improving the makeup of gut microbiomes have involved prebiotics, probiotics or drug therapies. Our goal was to take a totally new approach—to remodel the microbiome.”
First it was human embryos. Now scientists are trying to develop another way to modify human DNA that can be passed on to future generations, NPR has learned.
Reproductive biologists at Weill Cornell Medicine in New York City are attempting to use the powerful gene-editing technique called CRISPR to alter genes in human sperm. NPR got exclusive access to watch the controversial experiments underway.
The research is aimed at finding new ways to prevent disorders caused by genetic mutations that are passed down from men — including some forms of male infertility. The team is starting with a gene that can increase the risk for breast, ovarian, prostate and other cancers.
Nearly one in 30 Americans over the age of 40 experience low vision—significant visual impairment that can’t be corrected with glasses, contact lenses, medication or surgery.
In a new study of patients with retinitis pigmentosa, an inherited degenerative eye disease that results in poor vision, Keck School of Medicine of USC researchers found that adapted augmented reality (AR) glasses can improve patients’ mobility by 50% and grasp performance by 70%.
“Current wearable low vision technologies using virtual reality are limited and can be difficult to use or require patients to undergo extensive training,” said Mark Humayun, MD, Ph.D., director of the USC Dr. Allen and Charlotte Ginsburg Institute for Biomedical Therapeutics, codirector of the USC Roski Eye Institute and University Professor of Ophthalmology at the Keck School.
The ability to edit genes in living organisms offers the opportunity to treat a plethora of inherited diseases. However, many types of gene-editing tools are unable to target critical areas of DNA, and creating such a technology has been difficult as living tissue contains diverse types of cells.
Now, Salk Institute researchers have developed a new tool—dubbed SATI—to edit the mouse genome, enabling the team to target a broad range of mutations and cell types. The new genome-editing technology, described in Cell Research on August 23, 2019, could be expanded for use in a broad range of gene mutation conditions such as Huntington’s disease and the rare premature aging syndrome, progeria.
“This study has shown that SATI is a powerful tool for genome editing,” says Juan Carlos Izpisua Belmonte, a professor in Salk’s Gene Expression Laboratory and senior author of the paper. “It could prove instrumental in developing effective strategies for target-gene replacement of many different types of mutations, and opens the door for using genome-editing tools to possibly cure a broad range of genetic diseases.”